These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30098325)

  • 1. Evaluating the Efficacy and Safety of Silodosin on Nocturia in Patients With Benign Prostatic Hyperplasia: A Multicenter, Prospective, Open-label, Single-arm, Phase IV Trial.
    Cho KJ; Lee JZ; Song YS; Choi JB; Kim DK; Kim YT; Kim JC
    Urology; 2018 Nov; 121():153-157. PubMed ID: 30098325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of 8-mg once-daily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (SILVER Study): a 12-week, double-blind, randomized, parallel, multicenter study.
    Choo MS; Song M; Kim JH; Lee KS; Kim JC; Kim SW; Yang SK; Lee JG; Lee JZ; Kim DK; Park WH; Kim KD; Na YG; Kwon DD; Paick JS
    Urology; 2014 Apr; 83(4):875-81. PubMed ID: 24529580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
    Yoshida M; Origasa H; Seki N
    Low Urin Tract Symptoms; 2017 Sep; 9(3):176-186. PubMed ID: 28439987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study).
    Montorsi F; Gandaglia G; Chapple C; Cruz F; Desgrandchamps F; Llorente C
    Int J Urol; 2016 Jul; 23(7):572-9. PubMed ID: 26969887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Crossover Comparison of the Short-Term Efficacy and Safety of Single Half-Dose Silodosin and Tamsulosin Hydrochoride in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Takeshita H; Moriyama S; Arai Y; Washino S; Saito K; Chiba K; Horiuchi S; Noro A
    Low Urin Tract Symptoms; 2016 Jan; 8(1):38-43. PubMed ID: 26789541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study.
    Fusco F; Creta M; Longo N; Persico F; Franco M; Mirone V
    BMC Urol; 2018 Mar; 18(1):12. PubMed ID: 29502524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
    BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study.
    Shirakawa T; Haraguchi T; Shigemura K; Morishita S; Minayoshi K; Miyazaki J; Yamada Y; Miyake H; Tanaka K; Fujisawa M
    Int J Urol; 2013 Sep; 20(9):903-10. PubMed ID: 23252453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe].
    Chapple ChR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernandez Fernandez E
    Urologiia; 2012; (5):38-42, 44-5. PubMed ID: 23342615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH.
    Osman NI; Chapple CR; Tammela TL; Eisenhardt A; Oelke M
    World J Urol; 2015 May; 33(5):697-706. PubMed ID: 25712312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia.
    Yoshida T; Kinoshita H; Shimada S; Taguchi M; Matsuda T
    Urology; 2017 Aug; 106():153-159. PubMed ID: 28431996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
    Novara G; Chapple CR; Montorsi F
    BJU Int; 2014 Sep; 114(3):427-33. PubMed ID: 24571313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms.
    Shin YS; Zhang LT; Zhao C; Kim YG; Park JK
    Clin Interv Aging; 2014; 9():1021-30. PubMed ID: 25031529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of silodosin on sexual function - realistic picture from the everyday clinical practice.
    Capogrosso P; Serino A; Ventimiglia E; Boeri L; Dehò F; Damiano R; Briganti A; Montorsi F; Salonia A
    Andrology; 2015 Nov; 3(6):1076-81. PubMed ID: 26446512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms.
    Bae WJ; Bae JH; Kim SW; Chung BH; Kim JH; Kim CS; Lee HM; Lee KS; Yoo TK; Kim SI; Byun SS; Lee JY
    J Urol; 2013 Jul; 190(1):180-6. PubMed ID: 23357213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.
    Manjunatha R; Pundarikaksha HP; Madhusudhana HR; Amarkumar J; Hanumantharaju BK
    Indian J Pharmacol; 2016; 48(2):134-40. PubMed ID: 27127315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin.
    Ito H; Sano F; Ogawa T; Yao M
    Int J Urol; 2014 Jan; 21(1):108-12. PubMed ID: 23662900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-inferiority of silodosin 4 mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia: a multicenter, randomized, parallel-group study.
    Seki N; Takahashi R; Yamaguchi A; Ito K; Takayama K; Nanri K; Kamiryo Y; Yamashita H; Komine S; Miyazaki Y; Uozumi J; Naito S
    Int J Urol; 2015 Mar; 22(3):311-6. PubMed ID: 25597862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.